References
- 1. Fenaux P, Haase D, Sanz GF, Santini V, Buske C. Clinical practice guidelines Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25(Suppl 3):57-69. DOI: 10.1093/annonc/mdu180.10.1093/annonc/mdu18025185242
- 2. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised International Prognostic Scoring System for Myelodisplastic Syndromes. Blood. 2012 Sep; 120(12):2454-65. DOI: 10.1182/blood-2012-03-420489.10.1182/blood-2012-03-420489442544322740453
- 3. Bănescu C, Benedek I, Duicu C, Demian S, Voidăzan S. Cytogenetic findings and their prognostic impact in myelodysplastic syndrome patientes. Revista Română de Medicină de Laborator. 2011 Iun;2(19):139-47.
- 4. Duarte FB, Goncalves RP, Barbosa MC, Rocha Filho FD, de Jesus dos Santos TE, Nogueira dos Santos T, et al. Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome. Rev Bras Hemathol Hemother. 2014 Apr;36(3):196-201. DOI: 10.1016/j.bjhh.2014.03.007.10.1016/j.bjhh.2014.03.007410973425031059
- 5. Nolte F, Hofmann WK. Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncol. 2010 Mar;6(3):445-55. DOI: 10.2217/fon.09.175.10.2217/fon.09.17520222800
- 6. Bejar RK, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutation in Myelodysplastic Syndromes. N Engl J Med. 2011 Iun; 364: 2496-506.10.1056/NEJMoa1013343315904221714648
- 7. Porwit A, Saft L. The AML-MDS interface-leukemic transformation in myelodysplastic syndromes. J Hematop. 2011 May;4(2):69-79. DOI: 10.1007/ s12308-011-0088-6.10.1007/s12308-011-0088-6
- 8. Savic A, Cemerikic-Martinovic V, Dovat S, Rajic N, Urosevic I, Sekulic B, et al. “Angiogenesis and survival in patients with myelodysplastic syndrome”. Pathol Oncol Res. 2012 Jul;18(3):681-90. DOI: 10.1007/ s12253-012-9495-y.10.1007/s12253-012-9495-y22270865
- 9. Cheng CL, Hou HA, Jhuang JY, Lin CW, Chen CY, Tang JL, et al. High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes. Br J Cancer. 2011 Aug;105(7);975-82. DOI: 10.1038/ bjc.2011.340.10.1038/bjc.2011.340318595321878936
- 10. Ribatti D, Polimeno G, Vacca G, Marzullo A, Crivellato E, Nico B, et al. Correlation of bone marrow angiogenesis and mast cells with tryptase activity in myelodysplastic syndromes. Leukemia. 2002 Sep;16(9):1680-4. DOI: 10.1038/sj.leu.2402586.10.1038/sj.leu.240258612200681